PURPOSE: Prognostic and predictive markers in breast cancer are currently determined by single analysis of protein amounts. If RNA-based multi-gene analyses enter clinical practice, simultaneous determination of currently established markers like human epidermal growth factor receptor 2 (HER2), urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) would represent an elegant simplification. To investigate the correlation between RNA and protein levels, we assessed HER2, uPA and PAI-1 in patients with breast cancer. In addition, we evaluated the influence of these factors on patient outcome. METHODS: We collected tumour samples from 133 patients with primary breast cancer. Protein and mRNA levels were measured for HER2, uPA and PAI-1. Protein concentration was measured by ELISA, mRNA expression was analysed by Affymetrix A133U Gene Chip and validated by quantitative PCR. RESULTS: We were able to demonstrate a statistically significant correlation between mRNA and protein expression for HER2 (r = 0.67, P < 0.001) and uPA (r = 0.7, P < 0.001) but not for PAI-1 (r = 0.27). We observed a prognostic information for PAI-1 mRNA and protein values. Patients with high PAI-1 mRNA expression had a reduced 10-year disease-free survival (DFS) rate (60 vs. 70%, P = 0.071) and 10-year overall survival (OS) rate (68 vs. 79%, P = 0.034). Patients with PAI-1 protein levels above 14 ng/mg protein had a reduced disease-free (10-year DFS rate 54 vs. 71%, P = 0.006) and overall survival rate (10-year OS-rate 63 vs. 83%, P = 0.018). In the patient cohort with no chemotherapy, PAI-1 mRNA levels were the strongest prognostic factor for OS in univariate and multivariate analysis. CONCLUSIONS: Results of RNA-based multi-gene analyses of the prognostic and predictive markers HER2 and uPA correlate with the corresponding protein levels. This is not the case for PAI-1. However, PAI-1 mRNA expression might reveal new clinically relevant information in addition to PAI protein levels.
PURPOSE: Prognostic and predictive markers in breast cancer are currently determined by single analysis of protein amounts. If RNA-based multi-gene analyses enter clinical practice, simultaneous determination of currently established markers like humanepidermal growth factor receptor 2 (HER2), urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) would represent an elegant simplification. To investigate the correlation between RNA and protein levels, we assessed HER2, uPA and PAI-1 in patients with breast cancer. In addition, we evaluated the influence of these factors on patient outcome. METHODS: We collected tumour samples from 133 patients with primary breast cancer. Protein and mRNA levels were measured for HER2, uPA and PAI-1. Protein concentration was measured by ELISA, mRNA expression was analysed by Affymetrix A133U Gene Chip and validated by quantitative PCR. RESULTS: We were able to demonstrate a statistically significant correlation between mRNA and protein expression for HER2 (r = 0.67, P < 0.001) and uPA (r = 0.7, P < 0.001) but not for PAI-1 (r = 0.27). We observed a prognostic information for PAI-1 mRNA and protein values. Patients with high PAI-1 mRNA expression had a reduced 10-year disease-free survival (DFS) rate (60 vs. 70%, P = 0.071) and 10-year overall survival (OS) rate (68 vs. 79%, P = 0.034). Patients with PAI-1 protein levels above 14 ng/mg protein had a reduced disease-free (10-year DFS rate 54 vs. 71%, P = 0.006) and overall survival rate (10-year OS-rate 63 vs. 83%, P = 0.018). In the patient cohort with no chemotherapy, PAI-1 mRNA levels were the strongest prognostic factor for OS in univariate and multivariate analysis. CONCLUSIONS: Results of RNA-based multi-gene analyses of the prognostic and predictive markers HER2 and uPA correlate with the corresponding protein levels. This is not the case for PAI-1. However, PAI-1 mRNA expression might reveal new clinically relevant information in addition to PAI protein levels.
Authors: Mark D Sternlicht; Alison M Dunning; Dan H Moore; Paul D P Pharoah; David G Ginzinger; Koei Chin; Joe W Gray; Frederic M Waldman; Bruce A J Ponder; Zena Werb Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-11 Impact factor: 4.254
Authors: Remedios Castelló; Jose M Landete; Francisco España; Carlos Vázquez; Carlos Fuster; Sergio M Almenar; Luis A Ramón; Klaus-Peter Radtke; Amparo Estellés Journal: Thromb Res Date: 2007-01-29 Impact factor: 3.944
Authors: N Harbeck; C Thomssen; U Berger; K Ulm; R E Kates; H Höfler; F Jänicke; H Graeff; M Schmitt Journal: Breast Cancer Res Treat Date: 1999-03 Impact factor: 4.872
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Julia C Biermann; Leon Holzscheiter; Matthias Kotzsch; Thomas Luther; Marion Kiechle-Bahat; Fred C G J Sweep; Paul N Span; Manfred Schmitt; Viktor Magdolen Journal: Int J Mol Med Date: 2008-02 Impact factor: 4.101
Authors: Philippe Leissner; Thibault Verjat; Thomas Bachelot; Malick Paye; Alexander Krause; Alain Puisieux; Bruno Mougin Journal: BMC Cancer Date: 2006-08-31 Impact factor: 4.430
Authors: Marko Buta; Radan Džodić; Igor Đurišić; Ivan Marković; Tijana Vujasinović; Milan Markićević; Dragica Nikolić-Vukosavljević Journal: Tumour Biol Date: 2015-05-21
Authors: Christine Schröder; Isabell Witzel; Volkmar Müller; Sylke Krenkel; Ralph M Wirtz; Fritz Jänicke; Udo Schumacher; Karin Milde-Langosch Journal: J Cancer Res Clin Oncol Date: 2011-05-18 Impact factor: 4.553
Authors: Lothar Böhm; Antonio Serafin; John Akudugu; Pedro Fernandez; Andre van der Merwe; Naseem A Aziz Journal: J Cancer Res Clin Oncol Date: 2013-04-18 Impact factor: 4.553
Authors: József Dudás; Alexandra Fullár; Mario Bitsche; Volker Schartinger; Ilona Kovalszky; Georg Mathias Sprinzl; Herbert Riechelmann Journal: Exp Cell Res Date: 2011-06-02 Impact factor: 3.905
Authors: Matthias Kotzsch; Viktor Magdolen; Thomas Greither; Matthias Kappler; Matthias Bache; Christine Lautenschläger; Susanne Füssel; Alexander W Eckert; Thomas Luther; Gustavo Baretton; Peter Würl; Helge Taubert Journal: BMC Cancer Date: 2011-06-25 Impact factor: 4.430
Authors: Isabell Witzel; Karin Milde-Langosch; Marcus Schmidt; Thomas Karn; Sven Becker; Ralph Wirtz; Achim Rody; Elena Laakmann; Dina Schütze; Fritz Jänicke; Volkmar Müller Journal: Onco Targets Ther Date: 2014-11-28 Impact factor: 4.147
Authors: Omar Al-Janabi; Helge Taubert; Andrea Lohse-Fischer; Michael Fröhner; Sven Wach; Robert Stöhr; Bastian Keck; Max Burger; Wolf Wieland; Kati Erdmann; Manfred P Wirth; Bernd Wullich; Gustavo Baretton; Viktor Magdolen; Matthias Kotzsch; Susanne Füssel Journal: Biomed Res Int Date: 2014-04-29 Impact factor: 3.411
Authors: Michael Kenn; Karin Schlangen; Dan Cacsire Castillo-Tong; Christian F Singer; Michael Cibena; Heinz Koelbl; Wolfgang Schreiner Journal: Oncotarget Date: 2017-08-24